Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...

(OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose ...

First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median ...

Maky Zanganeh became a billionaire after shares of Summit Therapeutics, where she serves as co-CEO, soared following positive ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") , a biotechnology company focused on the treatment and prevention of cancer, today announced its strategic plan for a Phase 2 study for its breast ...

Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...

Shares in Anixa Biosciences rose after the company outlined plans for a Phase 2 study of its breast cancer vaccine. Shares were recently up 5% at $3.39.

The NMIBC market is gaining momentum, with ~13 therapies anticipated to enter key markets by 2034. DelveInsight projects that three critical drugs will secure billion-dollar markets across the 7MM by ...

Announces focus on therapeutic approach; resulting in a faster and more cost-effective path to approval SAN JOSE, Calif., Sept. 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Compan ...

Maky Zanganeh, Co-CEO of Summit Therapeutics' owns 5% of the biopharmaceutical company and stock options. One of the 34 ...

Today, the industry leader in wellness technology, Therabody, added five new innovations and four limited editions of bestselling products to their ecosystem of science-backed solutions. The latest ...